New KINECT-PRO™ Analysis Shows INGREZZA® Achieves High Remission Rates in Tardive Dyskinesia

Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced new findings from a post-hoc analysis of its Phase 4 KINECT-PRO™ study. The results confirm that once-daily INGREZZA® (valbenazine) capsules led to robust rates of symptomatic remission in tardive dyskinesia (TD), alongside sustained improvements in patient-reported outcomes (PROs).

These results were presented at Psych Congress 2025 in San Diego.

Key Findings

• First-of-its-kind analysis reporting both TD remission and PRO improvements.
• Symptomatic remission at Week 24 was achieved by 57.8% of patients (26/45).
  - 58.3% at 40 mg
  - 44.4% at 60 mg
  - 62.5% at 80 mg
• Remission defined as AIMS score ≤1 (“minimal” or “none”) across body regions (items 1–7).
• Patients in remission reported meaningful gains in daily life, function, and well-being.

Impact on Patients’ Lives

Among patients who achieved remission:

"These results suggest remission is achievable sooner than expected, across mild to severe TD cases. Patients who reached remission also experienced significant physical, social, and emotional improvements—making remission an important treatment goal with INGREZZA."

• Dr. Sanjay Keswani, CMO of Neurocrine

About KINECT-PRO™

• Design: Phase 4, open-label study reflecting real-world TD patients.
• Population: Patients with schizophrenia, schizoaffective disorder, bipolar disorder, or major depression who had mild-to-severe TD and associated distress.
• Dosing: Started at 40 mg daily; adjusted to 60 or 80 mg by Week 16; stable dose through Week 24.
• Outcome: Demonstrated both clinical remission and validated PRO improvements.
• Safety: Consistent with INGREZZA’s known profile; no new concerns identified.

Why This Matters

• First and only study to show validated PRO improvements with a VMAT2 inhibitor in TD.
• Supports the Tardive Dyskinesia Impact Scale (TDIS™) as a key tool for assessing quality-of-life outcomes.
• Adds to the growing body of evidence that INGREZZA can reduce TD severity and achieve remission.

Additional Neurocrine Presentations at Psych Congress 2025

• Osavampator (NBI-1065845/TAK-653): Phase 2 SAVITRI™ results in major depressive disorder.
• Multiple poster presentations on TD symptom relief, functional improvements, and quality-of-life outcomes with valbenazine.

About Tardive Dyskinesia

• Affects an estimated 800,000 adults in the U.S.
• Caused by long-term use of dopamine-blocking medications (e.g., antipsychotics, GI drugs).
• Symptoms include involuntary movements of the face, torso, or limbs, which can be persistent, disruptive, and often irreversible.

About INGREZZA® (valbenazine)

• FDA-approved for:
  - Tardive dyskinesia in adults
  - Chorea associated with Huntington’s disease
• Dosing: Once daily, with no required titration.
• Available as: Capsules (40, 60, 80 mg) and INGREZZA SPRINKLE® for patients with swallowing difficulties.

About Neurocrine Biosciences

A neuroscience-focused biopharma company developing treatments for neurological, neuroendocrine, and psychiatric disorders, including TD, Huntington’s disease, congenital adrenal hyperplasia, endometriosis, and uterine fibroids.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!